Skip to main content

Table 1 Summary of studies and treatment arms included in the mixed treatment comparison analysis (primary analysis)

From: Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD – mixed treatment comparisons of clinical efficacy

  N (%)   N (%)
Total studies 33 Total treatment arms 104
Endpoint reported   Treatments  
Change from baseline in FEV1 28 (85) Placebo 14 (13)
Annual rate of moderate/severe exacerbations 15 (45) FF/VI 50/25 QD 3 (3)
Change from baseline in total SGRQ 20 (61) FF/VI 100/25 QD 7 (7)
Exacerbation history   FF/VI 200/25 QD 3 (3)
At least 1 14 (42) FF 100 QD 2 (2)
At least 2 3 (9) FF 200 QD 1 (1)
Not reported 16 (48) VI 25 QD 4 (4)
% Predicted FEV1   FP/SAL 250/50 BID 8 (8)
<50% 13 (39) FP/SAL 500/50 BID 14 (13)
50%–70% 16 (48) FP/SAL 500/50 BID + TIO18 QD 1 (1)
>70% 4 (12) SAL 50 BID 10 (10)
Mean age reported 63.79 SAL 50 BID + theophylline 1 (1)
Mean proportion male 0.73 FP 250 BID 1 (1)
Mean proportion current smokers 0.46 FP 500 BID 3 (3)
   FP 500 BID + TIO 18 QD 1 (1)
   BUD/FORM 160/9 BID 3 (3)
   BUD/FORM 400/12 BID 9 (9)
   BUD 160 BID 1 (1)
   BUD 320 BID 3 (3)
   FORM 9 BID 8 (8)
   MMF 400 BID 1 (1)
   MMF/FORM 200/10 BID 1 (1)
   MMF/FORM 400/10 BID 1 (1)
   TIO 18 QD 3 (3)
   BDP(extra fine)/FORM 200/12 BID 1 (1)
  1. Note: All stated nominal doses are mcg.
  2. BDP = beclomethasone dipropionate, BID = twice daily, BUD = budesonide, FORM = formoterol, FEV 1 = forced expiratory volume in one second, FF = fluticasone furoate, FP = fluticasone propionate, MMF = mometasone furoate, QD = once daily, SAL = salmeterol, SGRQ = St George’s Respiratory Questionnaire, TIO = tiotropium, VI = vilanterol.